Pharma Capital

Clinigen hails EC label change for oncology drug

The label change relates to Cardioxane, which is given to protect the heart against certain chemotherapies called anthracyclines
A child
Doctors can now consider using the drug to protect children

Clinigen Group PLC (LON:CLIN) said the European Commission (EC) has approved an update to the product information for a key oncology product that would allow doctors to consider its use in children.

The label change relates to Cardioxane, which is given to protect the heart against certain chemotherapies called anthracyclines.

Its use was restricted in 2011. But, following extensive work by the Clinigen team, paediatric oncologists and cardiologists, the company was issued with a positive opinion by the EMA Committee for Medicinal Products for Human Use in May.

READ: Clinigen Group: A billion pound AIM company

Major milestone

Chief executive Shaun Chilton called the label change a “major regulatory achievement”.

Merav Edan, head of regulatory Specialty Pharmaceuticals of Clinigen, added: “EC approval is the final step to ensuring that the paediatric oncologists can effectively manage cardiotoxicity associated with anthracycline chemotherapy by using Cardioxane when needed.

WATCH: Clinigen's Shaun Chilton 'couldn't be happier' with full year performance

“Not only that, the additional changes to the Cardioxane product information will extend its use in the adult population.”

Ian_55ae0ddd437b7.jpg
Why Invest In Clinigen Group PLC? Read More Here

Register here to be notified of future CLIN Company articles
View full CLIN profile

Clinigen Group PLC Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.